2025 is set to be the most consequential year in healthcare policy since the 2017 Affordable Care Act (ACA) repeal debate. With key regulatory shifts on the horizon—ranging from ACA subsidy expirations to Medicare payment reforms and 340B drug pricing battles—stakeholders must stay ahead of the changes. This exclusive research report from Washington Analysis breaks down the critical developments that will reshape the healthcare landscape and impact key industry players.
What You’ll Learn:
- The impact of ACA enhanced subsidy expiration and potential policy responses.
- Ongoing litigation and legislative actions surrounding 340B drug pricing reform.
- The future of Medicare site-neutral payments and how they could affect providers.
- The implications of healthcare REIT reform on hospital lease agreements.
- Legislative risks and opportunities for pharmaceuticals, PBMs, and rare disease therapies.
- Key regulatory and financial considerations for healthcare providers, insurers, and investors.
Analysis contributions:
Laura Hobbs, Senior Vice President - Healthcare Policy
Tatiana Brown Johnson, Senior Vice President - Healthcare Policy
Monet Stanford, Senior Vice President - Healthcare Policy
Ryan Visnovec, Research Assistant
